Published online Aug 4, 2015. doi: 10.5492/wjccm.v4.i3.251
Peer-review started: August 22, 2014
First decision: September 28, 2014
Revised: April 15, 2015
Accepted: April 27, 2015
Article in press: April 29, 2015
Published online: August 4, 2015
Core tip: The management of tachyarrhythmia is important but it is often difficult because of unstable hemodynamics in septic patients. Landiolol is an ultra-short-acting β1 selective adrenoceptor antagonist. It exerts a more potent negative chronotropic effect and a lesser effect on blood pressure than other β blockers. In fact, landiolol significantly reduced heart rate without any deterioration of hemodynamics in this study. The most impressive finding is high conversion rate to sinus rhythm immediately after landiolol administration. Landiolol could control not only heart rate but also cardiac rhythm in septic patients with supraventricular tachyarrhythmias. Landiolol safely reduced heart rate and, in part, converted to sinus rhythm in septic patients with supraventricular tachyarrhythmia. Landiolol could be a valuable and suitable drug for managing supraventricular tachyarrhythmias in patients with sepsis.